Acquired resistance to miriplatin in rat hepatoma AH109A/MP10 is associated with increased Bcl-2 expression, leading to defects in inducing apoptosis

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 1011-1018

  Hanada, Mitsuharu ^a   Takasu, Hideo ^a   Kitaura, Makoto ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Acquired resistance; Bcl 2; Cisplatin; Hepatocellular carcinoma; Miriplatin

Indexed keywords

(CYCLOHEXANE 1,2 DIAMINE N,N')BIS(TETRADECANOATO O)PLATINUM; ANTINEOPLASTIC AGENT; CISPLATIN; DIAMINOCYCLOHEXANE; DICHLORO(1,2 CYCLOHEXANEDIAMINE N,N')PLATINUM; DRUG CARRIER; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; OXALIPLATIN; PLATINUM COMPLEX; PROTEIN BCL 2; PROTEIN INHIBITOR; PROTEIN MLH1; UNCLASSIFIED DRUG; YC 137;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CROSS RESISTANCE; DNA ADDUCT; DNA DRUG COMPLEX; DNA REPAIR; DRUG ACCUMULATION; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS;

EID: 77957331310     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000949     Document Type: Article

References (22)

1. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35: 1164-1171, 2002.
2. Llovet JM, Real MI, Montaña X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739, 2002.
3. Vogl TJ, Naguib NNN, Nour-Eldin NEA, et al: Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol 72: 505-516, 2009.
4. Maeda M, Uchida NA and Sasaki T: Liposoluble platinum (II) complexes with antitumor activity. Jpn J Cancer Res 77: 523-525, 1986.
5. Kishimoto S, Fukui M, Fukushima S and Nakano M: Application of a lipophilic platinum derivative contained in an oily lymphographic agent to intra-hepatic arterial chemotherapy. Reg Cancer Treat 1-2: 25-29, 1992.
6. Hanada M, Baba A, Tsutsumishita Y, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N and Nishikaku F: Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol 64: 473-483, 2009.
7. Hanada M, Baba A, Tsutsumishita Y, Noguchi T and Yamaoka T: Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats. Cancer Sci 100: 189-194, 2009.
8. Kishimoto S, Noguchi T, Yamaoka T, Fukushima S and Takeuchi Y: Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration. Biol Pharm Bull 23: 344-348, 2000.
9. Okusaka T, Okada S, Nakanishi T, Fujiyama S and Kubo Y: Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs 22: 169-176, 2004.
10. Okusaka T, Kasugai H, Ishii H and SM-11355 Japan Study Group: A randomized phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in comparison with zinostatin stimalamer in patients with hepatocellular carcinoma. J Clin Oncol 27: abs. 4583, 2009.
11. Kumada T, Nakano S, Takeda I, et al: Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 25: 87-92, 1997.
12. Stordal B, Pavlakis N and Davey R: Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treat Rev 33: 347-357, 2007.
13. Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320, 2005.
14. Kelland LR: DNA repair enzymes and platinum drug resistance in tumors. Am Assoc Cancer Res Eductional Book, pp209-213, 2008.
15. Danial NN: Bcl-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res 13: 7254-7263, 2007.
16. Real PJ, Cao Y, Wang R, Nikolovska-Coleska Z, Sanz-Ortiz J, Wang S and Fernandez-Luna JL: Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res 64: 7947-7953, 2004.
17. Heffeter P, Jungwirth U, Jakupec M, et al: Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updates 11: 1-16, 2008.
18. Kishimoto S, Miyazawa K, Terakawa Y, Ashikari H, Ohtani A, Fukushima S and Takeuchi Y: Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N′) bis(myristato)]platinum (II) suspended in lipiodol in a newly established cisplatin-resistant rat hepatoma cell line. Jpn J Cancer Res 91: 1326-1332, 2000. (Pubitemid 32042368)
19. Wu Y, Pradhan P, Havener J, Boysen G, Swenberg JA, Campbell SL and Chaney SG: NMR solution structure of an oxaliplatin 1,2-d(GG) intrastrand cross-link in a DNA dodecamer duplex. J Mol Biol 341: 1251-1269, 2004.
20. Chaney SG, Campbell SL, Bassett E and Wu Y: Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 53: 3-11, 2005.
21. Köhler B, Anguissola S, Concannon CG, Rehm M, Kögel D and Prehn JHM: Bid participates in genotoxic drug-induced apoptosis of HeLa cells and in essential for death receptor ligands' apoptotic and synergistic effects. PLoS ONE 3: e2844, 2008.
22. Wang X, Li M, Wang J, et al: The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells. Biochem Pharmacol 71: 1540-1550, 2006.